Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study)
Influenza and Other Respiratory Viruses · 2023
DOI: 10.1111/irv.13167 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Influenza and Other Respiratory Viruses, 2023. Verfasst von Philipp Kohler und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology Cantonal Hospital St Gallen St Gallen Switzerland. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesamt für Gesundheit.
Abstract (Originalsprache)
The effects of different types of pre‐existing immunity on the frequency of clinical symptoms caused by the SARS‐CoV‐2 breakthrough infection were prospectively assessed in healthcare workers during the Omicron period. Among 518 participants, hybrid immunity was associated with symptom reduction for dizziness, muscle or limb pain and headache as compared to vaccination only. Moreover, the frequencies of dizziness, cough and muscle or limb pain were lower in participants who had received a booster vaccine dose. Thus, hybrid immunity appeared to be superior in preventing specific symptoms during breakthrough infection compared to vaccination alone. A booster vaccine dose conferred additional symptom reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and Hospital Epidemiology Cantonal Hospital St Gallen St Gallen Switzerland.
- Epitrack Recife Brazil.
- Department of Economics University of Zurich Zurich Switzerland.
- Psychiatry Services of the Canton of St. Gallen (South) Pfäfers Switzerland.
- Clienia Littenheid AG, Private Clinic for Psychiatry and Psychotherapy Littenheid Switzerland.
- Division of Occupational Health Kantonsspital Baden Baden Switzerland.
ORCID-Profile: Philipp Kohler, Allison McGeer, Stefan P Kuster
Förderung
- Bundesamt für Gesundheit
Zitieren
APA
Kohler, P., Babouee Flury, B., Güsewell, S., Egger, T., Leal, O., Brucher, A., Lemmenmeier, E., Meier Kleeb, D., Möller, J. C., Ortner, M., Rieder, P., Ruetti, M., Schmid, H. R., Stocker, R., Vuichard-Gysin, D., Speer, O., Wiggli, B., Besold, U., McGeer, A., …, & SURPRISE Study Group (2023). Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study). Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13167
Vancouver
Kohler P, Babouee Flury B, Güsewell S, Egger T, Leal O, Brucher A, et al. Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study). Influenza and Other Respiratory Viruses. 2023. doi:10.1111/irv.13167
BibTeX
@article{Kohler2023,
author = {Kohler, Philipp and Babouee Flury, Baharak and Güsewell, Sabine and Egger, Thomas and Leal, Onicio and Brucher, Angela and Lemmenmeier, Eva and Meier Kleeb, Dorette and Möller, J Carsten and Ortner, Manuela and Rieder, Philip and Ruetti, Markus and Schmid, Hans-Ruedi and Stocker, Reto and Vuichard-Gysin, Danielle and Speer, Oliver and Wiggli, Benedikt and Besold, Ulrike and McGeer, Allison and Risch, Lorenz and Friedl, Andrée and Schlegel, Matthias and Vernazza, Pietro and Kahlert, Christian R and Kuster, Stefan P and SURPRISE Study Group, SURPRISE Study Group},
title = {Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study)},
journal = {Influenza and Other Respiratory Viruses},
year = {2023},
doi = {10.1111/irv.13167}
}
EUVIMED